ELPA Educational Training – DAY TWO, 11th November 2020
Differently from day one, the second day of ELPA Educational Training on November 11, 2020, was entirely dedicated to presentations from Pharma Companies. The meeting started with ELPA President Marko Korenjak welcoming everybody.
Dr. Elliot Norry, the representative of Adaptimmune, delivered the first presentation. He went deep into the work the company is doing concerning liver cancer. He presented a complex and personalized therapy and the related stage of clinical trials. He also tried to sketch what would come next, and he stressed the importance for patients to understand how a treatment works. However, it is complicated to translate complex medical procedures into more straightforward content. Yet, the company has social media channels with materials that can be used by patients and advocates. One of the most exciting characteristics of this session was the attendees’ involvement. They were able to ask many questions and discuss this topic from their points of view.
After the break, some representatives from Mirum took the floor. Dr. Ed Tucker presented how Mirum engaged with patients and gave an overview of the ongoing clinical trial and treatments. ELPA was delighted to hear from such a young but engaged company. Mostly because they are totally focused on rare liver diseases both in children and in adults. The fact that too many liver disease patients still fall victim to the unknown and for many liver diseases, their causes, as well as effective diagnostics, treatments, and cures remain unclear, motivated the audience to ask many questions, especially about paediatric clinical trials.
Before the end of the meeting ELPA President, Marko Korenjak reminded everybody of the topics of the next Wednesday’s ELPA Educational training webinar, inviting the audience to join on November 18, for another exciting ELPA training day.